Rhythm Pharmaceuticals (RYTM) Operating Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Operating Expenses data on file, last reported at $112.5 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $112.5 million, up 41.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $414.5 million (up 33.94% YoY), and the FY2025 annual result was $381.8 million, down 3.5% from the prior year.
• Operating Expenses climbed to $112.5 million in Q1 2026 per RYTM's latest filing, from $104.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $165.9 million in Q1 2024 and troughed at $43.6 million in Q3 2022.
• A 5-year average of $79.7 million and a median of $69.6 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 159.15% in 2024, then slumped 51.94% in 2025.
• A 5-year view of Operating Expenses shows it stood at $50.9 million in 2022, then climbed by 28.7% to $65.5 million in 2023, then climbed by 26.85% to $83.1 million in 2024, then rose by 25.55% to $104.3 million in 2025, then rose by 7.82% to $112.5 million in 2026.
• Business Quant data shows RYTM's Operating Expenses at $112.5 million in Q1 2026, $104.3 million in Q4 2025, and $104.0 million in Q3 2025.